AGEP Webinar "Tackling Antimicrobial Resistance: Benchmarking pharmaceutical industry’s performance"

The Antimicrobial Resistance Benchmark is the first independent report to compare what pharmaceutical companies are doing to control drug resistance. Published in January 2018 at the Annual Meeting of the World Economic Forum in Davos, the Benchmark evaluates 30 pharmaceutical companies, a cross-section of the industry, in three areas: antimicrobial R&D, antibiotic manufacturing & production, and appropriate access & responsible use (stewardship) of antimicrobial products on the market.

Start

25. Juni 2018 - 15:00

End

25. Juni 2018 - 17:00

Join the AGEP Webinar on the Alumniportal Deutschland!

When: Monday, 25 June 2018, 15:00 (CET)

Where: www.alumniportal-deutschland.org/en/digital-learning/webinars/antimicrobial-resistance/

 

The Antimicrobial Resistance Benchmark is the first independent report to compare what pharmaceutical companies are doing to control drug resistance. Published in January 2018 at the Annual Meeting of the World Economic Forum in Davos, the Benchmark evaluates 30 pharmaceutical companies, a cross-section of the industry, in three areas: antimicrobial R&D, antibiotic manufacturing & production, and appropriate access & responsible use (stewardship) of antimicrobial products on the market. The Benchmark has been developed as a tool for companies, policy-makers, investors, NGOs and others to deepen pharmaceutical industry involvement in efforts to curb AMR.

In this talk we will discuss the relevance of the pharmaceutical industry in tackling AMR in the global health arena, the market failure in the antibiotics’ market and what the industry is currently doing to solve the issue.

Antimicrobials are losing their effectiveness, accelerated mostly by their misuse in humans, animals and crops. These medicines must be used sparingly, in order to minimize the chances for bacteria and other pathogens to outsmart them. There is now wide recognition at the highest political levels that more needs to be done to slow the pace of antimicrobial resistance (AMR). Action is needed from all levels of society – including policy-makers, healthcare professionals, environmentalists, veterinary sector and agricultural sectors and civil society. Pharmaceutical companies, as developers, producers and suppliers of antimicrobial treatment, must also take action. Drawing on its expertise in developing industry metrics related to public health, the Access to Medicine Foundation has developed the Antimicrobial Resistance Benchmark, the first independent and public tool for measuring how pharmaceutical companies are responding to AMR.

The goal of the Antimicrobial Resistance Benchmark is to guide and incentivize pharmaceutical companies to fulfil their potential in limiting AMR. It maps how a cross-section of pharmaceutical industry is responding to AMR against a consensus view on where they can and should be making progress.

The way in which pharmaceutical companies manage access-to-medicine risks and opportunities can have significant impacts on their financial performance. Companies’ Investors engage with the Access to Medicine Foundation to receive guidance and support based on our daily analysis of developments in the pharmaceutical sector, being one of the key players to drive change in pharmaceutical companies and access to medicines.